CRED ERP 25

01/07/2025

Example

• Company requests a scientific advice with regard to a future MAA for a medicinal products containing an active substance that has not yet been authorised before in NL; • During meeting it is concluded that underlying documentation for the proposed legal base (WEU) might not be adequate/sufficient for the assessment of the benefit/risk balance; • Instead of requesting a follow-up advice the company submits the MAA under legal base 8(3); • Major concerns with regard to quality and completeness of the submitted documentation; → Interaction and dialogue are important: if advice is not clear than request clarification and/or follow-up advice

The Organisation for Professionals in Regulatory Affairs

21

Take-home messages

➢ Scientific advice to be asked before dossier is finalised/study performed ➢ Be aware: if you request scientific advice, adherence is recommended / deviation is difficult; ➢ Make sure that all participants speak and understand English (or Dutch in case of meeting at MEB with only Dutch people) ➢ Pre-submissionmeeting useful in case unexperienced company/first DCP e.g to discuss steps of procedure/possible strategy

➢ See also later in this presentation (talking to regulators)

The Organisation for Professionals in Regulatory Affairs

22